Bioorganic and Medicinal Chemistry Letters p. 3633 - 3637 (2014)
Update date:2022-09-26
Zhao, Huiping
Anyika, Mercy
Girgis, Antwan
Blagg, Brian S.J.
Hsp90 represents a promising target for the development of both anti-cancer and neuroprotective agents. Structure-activity relationship studies on novobiocin and novobiocin analogues, led to the development of KU-32 and recently, KU-596, as lead compounds for the potential treatment of neurodegenerative diseases. Similar to KU-32, we have demonstrated that upon replacement of the acetamide side chain present in KU-32 with a benzamide, this neuroprotective agent was transformed into a scaffold that manifests anti-proliferative activity. To assess structure-activity relationships for this new scaffold, a library of benzamide-containing novologues was prepared and evaluated against two breast cancer cell lines. Compound 14a manifested the most potent anti-proliferative activity from these studies and induced Hsp90-dependent client protein degradation in a concentration-dependent manner.
View MoreAnhui Qingyun Pharmaceutical and Chemical Co.,Ltd
Contact:+86-551-63633067
Address:Shuangfeng Road Hefei Anhui
Qingdao XinYongAn Chemicals Co., Ltd
Contact:+86-532-81107967
Address:Chengyang dual-port industrial park by the sea,Qingdao
Jinan Decheng Hemu Medical Technology Co.,Ltd.
Contact:+86-531-68650525
Address:NO.554 Zhengfeng Road High-new Technology Development Zone
Tangshan Moneide Trading Co., Ltd.
Contact:+86-315-8309571
Address:2-7-420 Jidong Building Materials Commercial Center, Tangshan, Hebei, 064000 China
KINHENG CHEMICAL(SHANGHAI)CO., LTD.
Contact:+8621-60490170
Address:Room401, No.28,Lane 189, Yangshupu Rd. Shanghai, China.
Doi:10.1002/chir.22433
(2015)Doi:10.1016/j.tetlet.2012.05.003
(2012)Doi:10.1021/ol301602h
(2012)Doi:10.1016/0040-4039(91)80210-W
(1991)Doi:10.1007/BF00630353
(1991)Doi:10.1016/S0040-4020(02)00577-X
(2002)